Balykova 2020.
Study characteristics | |
Methods | Open‐label RCT |
Participants | Inpatients; confirmed COVID‐19 (moderate) |
Interventions | Favipiravir, standard of care |
Outcomes | Time to clinical recovery, mortality, progression to invasive mechanical ventilation, significant changes in vital signs and clinical laboratory parameters, adverse events and serious adverse events, adverse events leading to drug discontinuation, and progression to non‐invasive ventilation |
Notes |